Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma
Selma Ugurel(Klinikum Bielefeld), Vera Rebmann(University of Duisburg-Essen), Rudolf Herbst(Helios Klinikum Erfurt), Claudia Pföhler(Saarland University), Peter A. Horn(University of Duisburg-Essen), Dirk Schadendorf(National Center for Tumor Diseases), Annette Paschen(University of Duisburg-Essen), Elisabeth Livingstone(German Cancer Research Center), Antje Sucker(German Cancer Research Center), Sabine Schramm(University of Würzburg), Lisa Zimmer(The University of Sydney), Jürgen C. Becker(Düsseldorf University Hospital), Kai Horny(German Cancer Research Center), Jochen Utikal(German Cancer Research Center), Christian U. Blank(The Netherlands Cancer Institute), Bastian Schilling(Goethe University Frankfurt)
Cited by 109
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k